SecBot SecBot
Biotech Drug Report Generated Jun 30, 2026

Vafseo

AKBA·Akebia Therapeutics, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved by FDA (Phase 3b TIW-dosing study ongoing)
Time to market
Already on the market (FDA approved March 27, 2024; commercial launch January 2025)
Why 4/10
Vafseo is already FDA-approved (March 2024) and commercially launched, with no pending PDUFA or pivotal new-indication readout, the defining binary has passed. The next hard catalyst is Phase 3b TIW-dosing topline data expected Q4 2026, which could support label expansion discussions but is not a make-or-break event. As an approved commercial-stage drug with no pending regulatory decision, the score is capped at 4.
Actionable Insight NEUTRAL

Watch Q4 2026 for Phase 3b TIW-dosing topline data, positive results could unlock label expansion for three-times-weekly dosing, a commercial accelerator. The bigger overhang is the stalled non-dialysis expansion path (VALOR terminated Oct 2025), which caps the addressable market. Monitor quarterly Vafseo net revenue growth and whether Vafseo can offset the Auryxia generic erosion (Teva launched generic March 2026).

Price Chart

Loading chart...

Executive Summary

Vafseo (vadadustat) is an oral HIF-PH inhibitor approved by the FDA in March 2024 for anemia due to chronic kidney disease in adults on dialysis. Akebia's commercial launch began January 2025, with Vafseo net revenue of $15.8M in Q1 2026 (up 32% YoY). A major positive catalyst hit on June 30, 2026, the VOICE trial interim analysis met stopping criteria, showing Vafseo reduced hospitalizations vs. standard ESAs. However, the stock has fallen ~51% over 12 months, weighed down by the October 2025 termination of the non-dialysis expansion (VALOR) trial and the March 2026 launch of generic competition for Auryxia (Akebia's other product). Vafseo is the central value driver at a company with a ~$248M market cap, high short interest (~14% of float), and a pipeline of early-stage rare kidney disease assets.

How It Works

Vafseo is an oral pill taken once daily (with potential for three-times-weekly dosing). It works by tricking the body into thinking it's at high altitude, which stimulates natural production of erythropoietin (EPO), the hormone that tells bone marrow to make more red blood cells. This helps correct anemia in kidney disease patients who can't produce enough EPO naturally. It's a HIF-PH inhibitor, a different approach than injectable ESA drugs (like Epogen) that deliver synthetic EPO from outside the body.

Trial Status

Vafseo was approved based on the Phase 3 INNO2VATE program. A Phase 3b TIW (three-times-weekly dosing) study (NCT06901505) is active, not recruiting, with ~353 patients enrolled and topline data expected Q4 2026. The Phase 4 VOICE outcomes trial (~2,200 patients) hit its interim stopping criteria on June 30, 2026, showing Vafseo was non-inferior and superior to standard ESAs on a composite of mortality and hospitalization. The planned Phase 3 VALOR trial for non-dialysis patients was terminated in October 2025 after the FDA rejected the trial design as too costly and time-consuming.

The Two-Sided Case

▲ Bull Case5
Vafseo is an oral alternative to injectable ESAs (the $1B+ dialysis anemia standard of care), offering convenience and a new mechanism, early real-world adoption shows rapid patient growth (60% increase in Q1 2026 vs Q4 2025) and ~1,025 prescribers as of Q1 2026
VOICE trial interim analysis (June 30, 2026) met stopping criteria, Vafseo showed a statistically significant reduction in hospitalizations vs. ESAs with a win odds of 1.16, a powerful real-world evidence point that could drive formulary wins and physician adoption
Prescribing access expanded to cover ~275,000 dialysis patients (~100% of U.S. dialysis centers) through contracts with DaVita, Fresenius, DCI, and IRC, positioning Vafseo for continued share gains
Consensus analyst price target of $4.20 (mean) vs. ~$1.13 current price suggests significant upside if the commercial ramp meets expectations; 5 of 6 analysts rate Buy or Overweight
INNO2VATE post-hoc data presented at ASN Kidney Week 2025 showed vadadustat had a statistically significant lower risk of death or hospitalization compared to darbepoetin alfa
▼ Bear Case5
The non-dialysis expansion path (VALOR trial) was terminated in October 2025 after the FDA demanded a prohibitively large and costly trial design, this caps Vafseo's addressable market to the ~550K dialysis patients, leaving the larger non-dialysis CKD anemia population off limits
Akebia is not yet profitable; the legacy Auryxia franchise is under pressure from Teva's generic launch (March 2026), and Q1 2026 Auryxia revenue fell to $36.2M from $43.8M a year earlier, creating a revenue hole Vafseo must fill
Direct competition from GSK's Jesduvroq (daprodustat), the first oral HIF-PHI approved in the U.S. (Feb 2023) for dialysis patients, plus entrenched use of injectable ESAs (Epogen/Procrit) with decades of clinical data
Institutional investors trimmed positions aggressively in Q1 2026, Morgan Stanley cut 53%, Renaissance Technologies cut 49%, and Legal & General nearly exited (down 91%), suggesting wavering confidence in the commercial trajectory
The stock is down ~51% over 12 months and trades near the low end of its 52-week range ($0.82-$4.08); short interest of ~14% of float with 4.14 days to cover indicates elevated bearish sentiment

Upcoming Catalysts

  • Phase 3b TIW-dosing topline data (Q4 2026), could enable label expansion for three-times-weekly dosing, a key commercial differentiator in dialysis centers
  • Full VOICE trial completion and formal publication (early 2027), the interim already hit, but full data could reinforce the hospitalization benefit thesis
  • VOICE data submission for presentation at an upcoming scientific meeting
  • Praliciguat Phase 2 initial data for focal segmental glomerulosclerosis (FSGS), rare kidney disease pipeline
  • Quarterly earnings reports tracking Vafseo revenue growth vs. Auryxia erosion

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Akebia Therapeutics, Inc. 8-K AKBA ·Originating report

Sources · 13

Hover a chip for the title
1 drugstorenews.com2 drugs.com3 ir.akebia.com4 biospace.com5 tipranks.com6 stocktitan.net7 vafseohcp.com8 pharmaphorum.com9 tickerreport.com10 nasdaq.com11 fool.com12 benzinga.com13 flash.stocksentinel.ai